These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

18 related items for PubMed ID: 19034245

  • 1. Optimizing dosage and duration therapy for chronic hepatitis C <<difficult-to-treat patients>>.
    Ladero JM.
    Ann Hepatol; 2008; 7(4):392-4. PubMed ID: 19034245
    [Abstract] [Full Text] [Related]

  • 2. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
    Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR, Pockros PJ, Lin A, Cupelli L, Duff F, Wang K, Nelson DR.
    Hepatology; 2008 Oct; 48(4):1033-43. PubMed ID: 18697207
    [Abstract] [Full Text] [Related]

  • 3. [Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotype 1 and 4 patients with slow virologic response].
    Kim IH.
    Korean J Hepatol; 2010 Jun; 16(2):201-5. PubMed ID: 20606507
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α-fetoprotein levels.
    Kajiwara E, Ooho A, Yamashita N.
    Hepatol Res; 2012 Mar; 42(3):254-63. PubMed ID: 22136198
    [Abstract] [Full Text] [Related]

  • 5. Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections.
    Koretz RL.
    ACP J Club; 2005 Mar; 142(1):10-1. PubMed ID: 15656551
    [No Abstract] [Full Text] [Related]

  • 6. A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection.
    Xiao N, Shi S, Zhuang H.
    Hepat Med; 2010 Mar; 2():99-109. PubMed ID: 24367210
    [Abstract] [Full Text] [Related]

  • 7. Optimizing dosage and duration therapy for chronic hepatitis C <<difficult-to-treat patients>>.
    Ladero JM.
    Ann Hepatol; 2008 Mar; 7(4):392-4. PubMed ID: 19034245
    [Abstract] [Full Text] [Related]

  • 8. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
    Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR, Pockros PJ, Lin A, Cupelli L, Duff F, Wang K, Nelson DR.
    Hepatology; 2008 Oct; 48(4):1033-43. PubMed ID: 18697207
    [Abstract] [Full Text] [Related]

  • 9. [Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotype 1 and 4 patients with slow virologic response].
    Kim IH.
    Korean J Hepatol; 2010 Jun; 16(2):201-5. PubMed ID: 20606507
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α-fetoprotein levels.
    Kajiwara E, Ooho A, Yamashita N.
    Hepatol Res; 2012 Mar; 42(3):254-63. PubMed ID: 22136198
    [Abstract] [Full Text] [Related]

  • 11. Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections.
    Koretz RL.
    ACP J Club; 2005 Mar; 142(1):10-1. PubMed ID: 15656551
    [No Abstract] [Full Text] [Related]

  • 12. Optimizing dosage and duration therapy for chronic hepatitis C <<difficult-to-treat patients>>.
    Ladero JM.
    Ann Hepatol; 2008 Mar; 7(4):392-4. PubMed ID: 19034245
    [Abstract] [Full Text] [Related]

  • 13. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
    Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR, Pockros PJ, Lin A, Cupelli L, Duff F, Wang K, Nelson DR.
    Hepatology; 2008 Oct; 48(4):1033-43. PubMed ID: 18697207
    [Abstract] [Full Text] [Related]

  • 14. [Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotype 1 and 4 patients with slow virologic response].
    Kim IH.
    Korean J Hepatol; 2010 Jun; 16(2):201-5. PubMed ID: 20606507
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α-fetoprotein levels.
    Kajiwara E, Ooho A, Yamashita N.
    Hepatol Res; 2012 Mar; 42(3):254-63. PubMed ID: 22136198
    [Abstract] [Full Text] [Related]

  • 16. Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections.
    Koretz RL.
    ACP J Club; 2005 Mar; 142(1):10-1. PubMed ID: 15656551
    [No Abstract] [Full Text] [Related]

  • 17. Optimizing dosage and duration therapy for chronic hepatitis C <<difficult-to-treat patients>>.
    Ladero JM.
    Ann Hepatol; 2008 Mar; 7(4):392-4. PubMed ID: 19034245
    [Abstract] [Full Text] [Related]

  • 18. Optimizing dosage and duration therapy for chronic hepatitis C <<difficult-to-treat patients>>.
    Ladero JM.
    Ann Hepatol; 2008 Mar; 7(4):392-4. PubMed ID: 19034245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 1.